

WHO BioHub System

Member States Briefing

3rd March 2022



WHO is working in accordance with WHA 74.7




WHO / Antoine Tardy

Paragraph 9.15:

- work together with Member States, the medical and scientific community, and laboratory and surveillance networks,
- to promote early, safe, transparent and rapid sharing of samples and genetic sequence data of pathogens of pandemic and epidemic, or other high-risk, potential,
- taking into account relevant national and international laws, regulations, obligations and frameworks, including, as appropriate, the International Health Regulations (2005), the Convention on Biological Diversity and the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization and the Pandemic Influenza Preparedness Framework and
- the importance of ensuring rapid access to human pathogens for public health preparedness and response purposes;".



Approach to developing the WHO BioHub System



Stream 1 pilot-testing update

 MS that inputted in the Standard Material Transfer Agreements 1 and 2 for non-commercial sharing

Pilot-testing countries:



Current variants available in the WHO BioHub Facility:

Provider Member State	Variant
Luxembourg	Alpha, Beta, Gamma, Delta
South Africa	Omicron
UK	Omicron



Stream 1 pilot-testing update



Omicron first reported to WHO from South Africa Day 0
Wednesday - 24 November 2021

WHO is notified by SA about intention to send BMEPP through the BioHub

Monday - 29 November 2021

WHO BioHub SMTA related materials signed

Saturday 4 December 2021

Booking form received from Provider


Monday and Tuesday - 6,7 December 2021


Courier pick up from Provider

Wednesday and Thursday – 8 & 9 December 2021

BMEPP arrival in WHO BioHub Facility

Thursday and Friday – 9 &10 December 2021





Average total days from request to delivery was 8.75 days



Stream 2 – updates on technical consultations with stakeholders



Research

Handling research results and appropriate recognition of contributions

Key (technical) stakeholders:

Lab networks, scientists and biorepositories etc





GSD

Sharing of Genetic Sequence Data

Key (technical) stakeholders:

Legal experts and civil society and industry, other UN agencies, etc





IP

Intellectual Property Rights

Key (technical) stakeholders:

Legal experts and civil society and industry, other UN agencies, etc





Access to benefits arising from the sharing of BMEPP


Difference between noncommercial and commercial benefits

Key (technical) stakeholders:

Legal experts esp. on Nagoya, civil society and industry involvement, etc



Upcoming technical consultation on ABS





Aim and questions to explore related to the technical consultation

Technical consultation aim: to line up key considerations that could inform further discussions on the design of the WHO BioHub System.

For the purpose of the consultation, MS may want to consider the following questions:



- 1. What do you consider to be the most important benefits the WHO BioHub System should deliver and to whom?
- 2. What are the benefits that your stakeholder group would find most difficult to provide, if you were to participate in the System?
- 3. What are potential access and benefit sharing arrangements for the WHO BioHub System that would advance public health goals in an epidemic or pandemic situation?



Thank you!

https://www.who.int/initiatives/who-biohub/

WHO Secretariat can be reached for any further inputs at: biohub@who.int

